We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$5.12B
1-Year Est. Return
314.02%
This Fund
S&P 500
This Quarter
Est. Return
+17.18%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.45B
AUM Growth
+$67.8M
(+2%)
Cap. Flow
-$174M
Cap. Flow
% of AUM
-5.03%
Top 10 Holdings %
Top 10 Hldgs %
43.57%
Holding
114
New
15
Increased
22
Reduced
33
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
+$110M |
| 2 |
AKRO
Akero Therapeutics
AKRO
|
+$64.9M |
| 3 |
Vir Biotechnology
VIR
|
+$45.6M |
| 4 |
Medtronic
MDT
|
+$40.2M |
| 5 |
VRNA
Verona Pharma
VRNA
|
+$35.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$142M |
| 2 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
+$137M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
+$94.1M |
| 4 |
Sanofi
SNY
|
+$41.8M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$38.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.57% |
| 2 | Financials | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CBAY
26
DELISTED
Cymabay Therapeutics
CBAY
| $40.9M | 1.18% |
3,733,255
-170,000
| -4% | -$1.58M |
|
27
Protagonist Therapeutics
PTGX
$8.67B
| $40.6M | 1.18% |
1,469,761
+504,609
| +52% | +$12.6M |
|
|
SWTX
28
DELISTED
SpringWorks Therapeutics
SWTX
| $40.3M | 1.17% |
1,537,431
-541,921
| -26% | -$14.2M |
|
29
Immatics
IMTX
$1.22B
| $40.3M | 1.17% |
3,491,500
| – | – |
|
30
Acrivon Therapeutics
ACRV
$62.9M
| $39M | 1.13% |
3,007,858
| – | – |
|
31
Nautilus Biotechnolgy
NAUT
$137M
| $35.3M | 1.02% |
9,111,151
| – | – |
|
32
Crinetics Pharmaceuticals
CRNX
$8.88B
| $35.1M | 1.02% |
1,946,937
-1,607,950
| -45% | -$32.1M |
|
33
Disc Medicine
IRON
$2.82B
| $33M | 0.95% |
+742,838
| New | +$26.4M |
|
34
Roivant Sciences
ROIV
$23.9B
| $31.6M | 0.91% |
3,131,736
+439,600
| +16% | +$3.93M |
|
35
Cogent Biosciences
COGT
$6.85B
| $31.5M | 0.91% |
2,659,470
+377,146
| +17% | +$4.33M |
|
36
Harmony Biosciences
HRMY
$2.07B
| $31.4M | 0.91% |
891,370
+791,370
| +791% | +$27.3M |
|
37
BridgeBio Pharma
BBIO
$16.7B
| $30.1M | 0.87% |
1,748,933
-158,100
| -8% | -$2.38M |
|
38
Establishment Labs
ESTA
$2.73B
| $29.2M | 0.84% |
424,924
-42,933
| -9% | -$2.97M |
|
39
Verrica Pharmaceuticals
VRCA
$96M
| $29.1M | 0.84% |
503,898
| – | – |
|
40
Illumina
ILMN
$29.6B
| $27.2M | 0.79% |
+149,060
| New | +$30.2M |
|
41
argenx
ARGX
$55.2B
| $26.9M | 0.78% |
+69,000
| New | +$27.1M |
|
|
MRTX
42
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $26M | 0.75% |
719,103
-855,031
| -54% | -$35.2M |
|
43
Relay Therapeutics
RLAY
$4.08B
| $24.4M | 0.71% |
1,943,097
| – | – |
|
44
Tarsus Pharmaceuticals
TARS
$2.53B
| $23.4M | 0.68% |
1,296,416
| – | – |
|
45
Rocket Pharmaceuticals
RCKT
$340M
| $23.2M | 0.67% |
1,168,363
+300,631
| +35% | +$6.07M |
|
|
46
BioMarin Pharmaceuticals
BMRN
$11.9B
| $22.8M | 0.66% |
263,207
-409,853
| -61% | -$38.6M |
|
47
Zymeworks
ZYME
$1.63B
| $20.9M | 0.6% |
2,416,232
-962,266
| -28% | -$8.62M |
|
48
Cabaletta Bio
CABA
$435M
| $19.9M | 0.58% |
1,545,000
+820,223
| +113% | +$8.9M |
|
49
Outset Medical
OM
$87.5M
| $19.7M | 0.57% |
60,157
-12,471
| -17% | -$3.8M |
|
50
Natera
NTRA
$36.4B
| $19.7M | 0.57% |
405,269
-301,945
| -43% | -$15.4M |
|
Similar funds
BG
TAM
CIA
AC
EIC
CIC
CS
NC
Perceptive Advisors's Q2 2023 Portfolio in Review
As of Q2 2023, Perceptive Advisors held 114 positions worth $3.45B, up 2% from $3.39B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Perceptive Advisors withdrew a net $174M in Q2 2023, closing 19 positions and reducing 33 holdings. Its most notable exit was Prometheus Biosciences, Inc. Common Stock, an estimated $137M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.
Against the trend, Perceptive Advisors opened a new position in Medtronic worth $41.1M.
- Perceptive Advisors's largest Q2 2023 buy was Medtronic: 467,000 shares worth $41.1M.
- Perceptive Advisors added most to Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2023, an estimated $110M increase.
- Perceptive Advisors's biggest Q2 2023 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $142M.
- Perceptive Advisors fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $137M.
- Perceptive Advisors's ten largest holdings make up 44% of its $3.45B portfolio in Q2 2023.
- Perceptive Advisors opened 15 new positions and closed 19 in Q2 2023.
- Perceptive Advisors's portfolio value rose 2% quarter-over-quarter to $3.45B.
Based on Perceptive Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.